WeCare specializes in providing a diverse range of probiotic strains and tailored solutions. Introducing our flagship product, WecLac Bacillus Coagulans BC99, we strive to enhance well-being through innovative probiotic formulations and applications.

With rising cases and a push for gentler solutions, Wecare Probiotics has stepped up, spotlighting Bifidobacterium animalis subsp. lactis BLa80—a natural probiotic derived from breast milk in Sichuan, China—as a promising answer to this pervasive issue.

At Wecare Probiotics Co., Ltd., a national high-tech enterprise specializing in probiotics and intestinal flora research, we are particularly excited about these findings. Our commitment to advancing human health through probiotic strains and application solutions aligns with the study's implications for improving gut microbiome diversity.

The aim of this study was to evaluate the impact of Bifidobacterium animalis subsp. lactis BLa80 on defecation, gastrointestinal symptoms, and quality of life in patients with irritable bowel syndrome with constipation (IBS-C)

According to statistics, the drinking population in China accounts for 33.8% of the total population (approximately 470 million people), with 26% (approximately 123 million people) being excessive drinkers.

Currently, numerous developed countries and regions around the world have implemented various policies to regulate the standards of the probiotics industry.